close-icon

Welcome

Connect with the future of healthcare

In the cancer diagnosis landscape, MSInsight rises to the challenge— detecting Microsatellite Instability (MSI) in patient DNA. MSI is a crucial biomarker in cancer care, as it is predictive of response to immunotherapy, but spotting it accurately is no walk in the park. Current ways of finding MSI in various cancers aren’t cutting it; they are either not sensitive enough or stuck dealing with specific types of cancer. MSInsight steps up to the plate with MSIcare, a brand-new diagnostic tool ready to tackle this need.

Completed 26 one day ago
171 investors
Investment achieved
555.917€
Target
500.000€
Invested
111.2%
111.2% INVESTED
Request a meeting
This campaign was live:
From: 28 June 2024
Until: 10 October 2024
Maturity

Prototype/preclinical

Premoney valuation

2.500.000

Estimated exit

2029-2030

Sector

Diagnosis

Equity offered

20%

Minimum investment

500

FR based flag
Equity L
Tax deduction L
close modal

Share this project on your website.

Copy and paste the following code into your content.

Overview: MSInsight

Valuation 2.500.000
Estimated return x34
% Offered 20%
Estimated exit 2029-2030
The company

Cancer management is undergoing a profound transformation. Precision medicine has led to significant advancements in tailoring the treatment of each tumor based on its molecular characteristics at the DNA level.

MSInsight aims to tackle the daily challenge healthcare providers face: decoding a complex biomarker at the patient’s DNA level, representative of a family of common cancers called Microsatellite Instability (MSI) cancer.

The detection of the MSI biomarker dramatically guides patient care and therapeutic choices toward an effective new treatment—immunotherapy. Indeed, oncologists need access to trusted insights to tailor their clinical decisions, which MSInsight can provide.

Nowadays, this diagnostic is systematically recommended for any newly identified tumor, regardless of the origin of the cancer tissue (pan-cancer). It also aids in the early detection of familial predispositions to develop this type of cancer (Lynch syndrome).

In clinical practice, this widespread adoption requires suitable methodologies to perform large-scale screening with high precision in pan-cancer that could potentially impact 13 million individuals worldwide yearly. And the current reference tests fall short of current needs.

Introducing a Novel Bioinformatics Platform

At MSInsight, we are shaping the future of MSI diagnosis, harnessing the potential of a high-throughput DNA analysis technology: Next-Generation Sequencing (NGS). NGS is already routinely used in clinics for other genomic biomarkers than MSI and promises to be highly efficient in evaluating MSI. However, the interpretation of the generated genomic data relies on sophisticated algorithms, and those currently available are not precise enough, resulting in diagnostic errors in up to 30% of cases, leading to dramatic consequences for patients.

In collaboration with a reputed research team in the field of MSI cancer (Inserm), extensive work has been done to understand the reasons behind the poor performance of current tests and propose new, clinically validated, and highly reliable algorithms.

We are developing MSIcare, a software incorporating state-of-the-art bioinformatics algorithms derived from our groundbreaking research. By analyzing genomic data obtained by clinical laboratories, MSIcare identifies MSI with unparalleled precision, whether from patient tumor tissue or a blood sample, and in ALL cancer types. The next stage of development will encompass the regulatory studies and certification of MSIcare, as an in vitro diagnostic medical device.

Our Ambition: To Become the One-Stop Shop MSI Diagnostic Solution

We strive to become the leading player in NGS-based MSI diagnostics, covering the entire patient journey from early detection to treatment response prediction. Our goal is to support healthcare professionals by providing reliable patient-specific information that will help monitor their patients and support their medical decision-making.

MSInsight initially targets the NGS oncology genomic testing market, estimated at $12 billion. MSInsight has significant growth potential, as the future lies in the widespread use of MSI diagnosis regardless of the stage of the disease and the tumor type, the democratization of NGS in clinical routine, and substantial investment by biopharmaceutical industries in immunotherapies targeting MSI cancers. Ultimately, our solutions will benefit hundreds of thousands of individuals worldwide, directly improving their care.

MSInsight will operate on a B2B model, engaging directly with the hospital and private NGS laboratories, specialized genomic service providers, and biopharma companies. The company has formulated a competitive pricing strategy rooted in a value-based approach. To broaden our market and reach more customers, MSInsight will collaborate with strategic distribution partners.

We anticipate achieving a revenue of over €22 million by 2030, deploying MSIcare initially in Europe and North America, and then Asia. Our strategy aims to expand into other markets with complementary applications, such as companion diagnostic tests by biopharma partnerships and genetic tests for hereditary MSI cancers.

How confident are we?

We rely on a solid medical foundation, as exposed below :

We genuinely tackle the shortcomings of market leaders. Our understanding of MSI detection complexity is robust. Independent publications and clinical demonstrations underscore our superiority to existing solutions. We have established collaborations with eminent research institutes and hospitals in the field, enabling access to unprecedented data collection for developing our models. We have partnered with diverse expert service providers for technological development, regulatory compliance, and prototyping. The current installations in labs are the bedrock of our legitimacy and are open to attractive perspectives.

Industry professionals recognize our project and take pride in it. It has garnered prizes and grants, including winning the 25th i-Lab award (€ 250k grant), progressing to the final stage of the EIC Accelerator, as well as awarding an extra €1.3 million grant to our research partner dedicated to our collaborative efforts.

Why is Capital Cell investing in this company?

MSInsight is introducing MSIcare, a cutting-edge platform for the precise detection of the MSI biomarker using Next-Generation Sequencing (NGS) technology. Traditional testing methods like PCR are slow, lack sensitivity, and are not scalable, making them unsuitable for widespread screening. Existing NGS-based tools have a false negative rate of up to 30%. In contrast, MSIcare boasts a clinically validated 0% false negative rate, offering a significant advancement in speed and accuracy. This makes MSIcare ideal for large-scale screening, diagnosis, and the development and monitoring of personalized therapies. Experts have praised the scientific and technological robustness of this proposal.

MSI screening is already a standard in colon cancer, with testing rates in the US increasing by 15% from 2019 to 2021. MSIcare's adaptability to various tumor and sample types broadens its market potential, and its superior performance suggests strong market uptake and penetration prospects. Additionally, sequencing results from MSIcare can identify other biomarkers. The platform is protected by two exclusive patents from Inserm and one co-owned with them, ensuring complete operational freedom. While some experts considered market share and revenue projections optimistic, the overall business plan is deemed solid.

Minimum investment: 500
Type of exit expected: Exclusive acquisition, buyout by an industry player in the diagnostic field
Drag-along rights
Tag-along rights
Tax deductions
Our company qualifies for French residents with a 50% tax incentive.
Main risks

Obtaining regulatory approval, essential for clinical use, and further clinical validation to confirm its efficacy are necessary steps.

Additionally, integrating MSIcare into standard care will involve demonstrating its significant benefits to healthcare systems and achieving market penetration will require effort in a competitive landscape.